Acticor Biotech SA
PAR:ALACT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Acticor Biotech SA
Accrued Liabilities
Acticor Biotech SA
Accrued Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accrued Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
A
|
Acticor Biotech SA
PAR:ALACT
|
Accrued Liabilities
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Valneva SE
PAR:VLA
|
Accrued Liabilities
€35m
|
CAGR 3-Years
31%
|
CAGR 5-Years
22%
|
CAGR 10-Years
18%
|
|
|
G
|
Genfit SA
PAR:GNFT
|
Accrued Liabilities
€3k
|
CAGR 3-Years
-91%
|
CAGR 5-Years
-77%
|
CAGR 10-Years
N/A
|
|
|
Inventiva SA
PAR:IVA
|
Accrued Liabilities
€5.5m
|
CAGR 3-Years
19%
|
CAGR 5-Years
14%
|
CAGR 10-Years
N/A
|
|
|
DBV Technologies SA
PAR:DBV
|
Accrued Liabilities
$14.3m
|
CAGR 3-Years
34%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
11%
|
|
|
Abivax SA
PAR:ABVX
|
Accrued Liabilities
€4.7m
|
CAGR 3-Years
27%
|
CAGR 5-Years
19%
|
CAGR 10-Years
18%
|
|
Acticor Biotech SA
Glance View
Acticor Biotech SAS engages in the research and development of an antithrombotic agent for the treatment of the acute thrombotic diseases. The company is headquartered in Paris, Ile-De-France and currently employs 22 full-time employees. The company went IPO on 2021-11-01. The firm is a clinical stage biopharmaceutical company, a spin-off from INSERM (French National Institute of Health and Medical Research), specialized in the research and development of medicines for the treatment of thrombotic diseases, in particular acute ischemic strokes and pulmonary embolisms. The group has one product in Phase II clinical development (Glenzocimab) and its products in pipeline are ACTIMIS, GARDEN, ACTISAVE and GREEN. Its partnering companies are Ouest Valorisation, Genopole, Medicine and Inserm.
